• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

长效注射用非典型抗精神病药物治疗的精神分裂症患者的笔迹运动学:ALPINE研究结果

Handwriting Kinematics in Patients with Schizophrenia Treated with Long-Acting Injectable Atypical Antipsychotics: Results From the ALPINE Study.

作者信息

Caligiuri Michael P, Weiden Peter J, Legedza Anna, Yagoda Sergey, Claxton Amy

机构信息

Department of Psychiatry, University of California, San Diego, CA, USA.

Alkermes, Inc., Waltham, MA, USA.

出版信息

Schizophr Bull Open. 2022 Mar 7;3(1):sgac018. doi: 10.1093/schizbullopen/sgac018. eCollection 2022 Jan.

DOI:10.1093/schizbullopen/sgac018
PMID:39144789
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11205961/
Abstract

Handwriting kinematics (HWKs) were assessed in the randomized controlled ALPINE study of 2 long-acting injectable antipsychotics started during an acute exacerbation of schizophrenia. This exploratory analysis examined the relationship between baseline HWKs and response to acute antipsychotic treatment. Adults with acute schizophrenia were assigned to aripiprazole lauroxil or paliperidone palmitate (groups combined for this analysis). Treatment response was defined as ≥20% reduction from baseline in Positive and Negative Syndrome Scale (PANSS) total score at week 4. Two HWK measures, peak velocity (decreases with greater dysfunction) and percentage of nonballistic movements (%NBM; increases with greater dysfunction), were captured in 4 handwriting tasks (complex loops, maximum speed circles, overlay circles, and left-right loops). Peak velocity and %NBM at baseline were compared between responders and nonresponders. The analysis included 143 patients (mean baseline PANSS total score, 94.5). PANSS responders ( = 67 [46.9%]) had a lower mean peak velocity (i.e., slower pen movements) on all HWK tasks at baseline compared with nonresponders ( = 76): complex loops, 8.8 versus 12.1 cm/s; maximum speed circles, 18.0 versus 23.7 cm/s; overlay circles, 12.6 versus 17.2 cm/s; and left-right loops, 11.2 versus 14.6 cm/s. PANSS responders had a greater %NBM on 3 tasks compared with nonresponders: complex loops, 57.1% versus 47.4%; overlay circles, 30.6% versus 24.3%; and left-right loops, 58.7% versus 47.0%. In this exploratory analysis, PANSS responders to aripiprazole lauroxil or paliperidone palmitate treatment at week 4 had lower baseline HWK movement velocities and greater baseline %NBM versus nonresponders, suggesting that baseline HWKs might predict response to these antipsychotic drugs.

摘要

在一项针对2种长效注射用抗精神病药物的随机对照ALPINE研究中,对精神分裂症急性加重期患者的笔迹运动学(HWKs)进行了评估。这项探索性分析研究了基线HWKs与急性抗精神病药物治疗反应之间的关系。成年急性精神分裂症患者被分配至阿立哌唑月桂酸盐组或帕利哌酮棕榈酸酯组(本分析将两组合并)。治疗反应定义为第4周时阳性和阴性症状量表(PANSS)总分较基线降低≥20%。在4项笔迹任务(复杂环路、最大速度圆圈、叠加圆圈和左右环路)中记录了2项HWK指标,即峰值速度(功能障碍越严重,速度越低)和非弹道运动百分比(%NBM;功能障碍越严重,该指标越高)。比较了反应者和无反应者的基线峰值速度和%NBM。该分析纳入了143例患者(基线PANSS总分均值为94.5)。与无反应者(n = 76)相比,PANSS反应者(n = 67 [46.9%])在基线时所有HWK任务上的平均峰值速度均较低(即笔运动较慢):复杂环路任务中,分别为8.8 cm/s和12.1 cm/s;最大速度圆圈任务中,分别为18.0 cm/s和23.7 cm/s;叠加圆圈任务中,分别为12.6 cm/s和17.2 cm/s;左右环路任务中,分别为11.2 cm/s和14.6 cm/s。与无反应者相比,PANSS反应者在3项任务中的%NBM更高:复杂环路任务中,分别为57.1%和47.4%;叠加圆圈任务中,分别为30.6%和24.3%;左右环路任务中,分别为58.7%和47.0%。在这项探索性分析中,第4周时对阿立哌唑月桂酸盐或帕利哌酮棕榈酸酯治疗有反应的PANSS患者,与无反应者相比,基线HWK运动速度较低,基线%NBM较高,这表明基线HWKs可能预测这些抗精神病药物的治疗反应。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ff67/11205961/3c522fd2aa37/sgac018_fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ff67/11205961/33092d193a14/sgac018_fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ff67/11205961/b33cd02a3fe1/sgac018_fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ff67/11205961/3c522fd2aa37/sgac018_fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ff67/11205961/33092d193a14/sgac018_fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ff67/11205961/b33cd02a3fe1/sgac018_fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ff67/11205961/3c522fd2aa37/sgac018_fig3.jpg

相似文献

1
Handwriting Kinematics in Patients with Schizophrenia Treated with Long-Acting Injectable Atypical Antipsychotics: Results From the ALPINE Study.长效注射用非典型抗精神病药物治疗的精神分裂症患者的笔迹运动学:ALPINE研究结果
Schizophr Bull Open. 2022 Mar 7;3(1):sgac018. doi: 10.1093/schizbullopen/sgac018. eCollection 2022 Jan.
2
Aripiprazole lauroxil 2-month formulation with 1-day initiation in patients hospitalized for an acute exacerbation of schizophrenia: exploratory efficacy and patient-reported outcomes in the randomized controlled ALPINE study.阿立哌唑月桂酰 2 个月剂型 1 天起始治疗住院精神分裂症急性加重患者:ALPINE 研究的探索性疗效和患者报告结局的随机对照研究。
BMC Psychiatry. 2021 Oct 8;21(1):492. doi: 10.1186/s12888-021-03420-x.
3
Effect of aripiprazole lauroxil in patients with acute schizophrenia as assessed by the Positive and Negative Syndrome Scale-supportive analyses from a Phase 3 study.阿立哌唑棕榈酸酯治疗精神分裂症阳性与阴性症状量表(PANSS)疗效的支持性分析:一项 3 期研究。
CNS Spectr. 2018 Aug;23(4):284-290. doi: 10.1017/S1092852917000396. Epub 2017 Jun 19.
4
Paliperidone palmitate and risperidone long-acting injectable in subjects with schizophrenia recently treated with oral risperidone or other oral antipsychotics.棕榈酸帕利哌酮和利培酮长效注射剂在近期使用利培酮或其他口服抗精神病药物治疗的精神分裂症受试者中的应用。
Neuropsychiatr Dis Treat. 2013;9:341-50. doi: 10.2147/NDT.S36438. Epub 2013 Mar 5.
5
A randomized, double-blind, placebo-controlled trial of aripiprazole lauroxil in acute exacerbation of schizophrenia.阿立哌唑月桂醇酯治疗精神分裂症急性加重的随机、双盲、安慰剂对照试验。
J Clin Psychiatry. 2015 Aug;76(8):1085-90. doi: 10.4088/JCP.14m09741.
6
Effect of aripiprazole lauroxil on agitation and hostility in patients with schizophrenia.阿立哌唑月桂醇对精神分裂症患者激越和敌意的影响。
Int Clin Psychopharmacol. 2016 Mar;31(2):69-75. doi: 10.1097/YIC.0000000000000106.
7
Paliperidone palmitate versus oral antipsychotics in recently diagnosed schizophrenia.棕榈酸帕利哌酮与口服抗精神病药物治疗新诊断精神分裂症的比较
Schizophr Res. 2015 Dec;169(1-3):393-399. doi: 10.1016/j.schres.2015.08.015. Epub 2015 Oct 1.
8
Factors Associated with Symptom Stabilization that Allow for Successful Transition from Once-Monthly Paliperidone Palmitate to Three-Monthly Paliperidone Palmitate: A Post Hoc Analysis Examined Clinical Characteristics in Chinese Patients with Schizophrenia.与症状稳定相关的因素使得从每月一次棕榈酸帕利哌酮成功过渡到每三个月一次棕榈酸帕利哌酮:一项事后分析研究了中国精神分裂症患者的临床特征。
CNS Drugs. 2024 Jan;38(1):55-65. doi: 10.1007/s40263-023-01056-x. Epub 2024 Jan 8.
9
Aripiprazole Lauroxil Compared with Paliperidone Palmitate in Patients with Schizophrenia: An Indirect Treatment Comparison.阿立哌唑月桂醇酯与棕榈酸帕利哌酮治疗精神分裂症患者的比较:间接治疗比较
Value Health. 2017 Jul-Aug;20(7):876-885. doi: 10.1016/j.jval.2017.03.010. Epub 2017 May 9.
10
Paliperidone extended release: a review of its use in the management of schizophrenia.帕利哌酮长效制剂:在精神分裂症治疗中的应用评价。
Drugs. 2010 Jul 9;70(10):1295-317. doi: 10.2165/11204840-000000000-00000.

本文引用的文献

1
Efficacy and Safety of a 2-Month Formulation of Aripiprazole Lauroxil With 1-Day Initiation in Patients Hospitalized for Acute Schizophrenia Transitioned to Outpatient Care: Phase 3, Randomized, Double-Blind, Active-Control ALPINE Study.阿立哌唑月制剂 1 日起始用于急性精神分裂症住院患者门诊治疗转换的疗效和安全性:第 3 阶段、随机、双盲、阳性对照 ALPINE 研究。
J Clin Psychiatry. 2020 May 19;81(3):19m13207. doi: 10.4088/JCP.19m13207.
2
The nature of bradykinesia in schizophrenia treated with antipsychotics.抗精神病药物治疗的精神分裂症患者运动迟缓的本质。
Psychiatry Res. 2019 Mar;273:537-543. doi: 10.1016/j.psychres.2019.01.058. Epub 2019 Jan 15.
3
Handwriting Analysis in Parkinson's Disease: Current Status and Future Directions.
帕金森病中的笔迹分析:现状与未来方向
Mov Disord Clin Pract. 2017 Nov 1;4(6):806-818. doi: 10.1002/mdc3.12552. eCollection 2017 Nov-Dec.
4
The acute efficacy of antipsychotics in schizophrenia: a review of recent meta-analyses.抗精神病药物治疗精神分裂症的急性疗效:近期荟萃分析综述
Ther Adv Psychopharmacol. 2018 Oct 8;8(11):303-318. doi: 10.1177/2045125318781475. eCollection 2018 Nov.
5
The utility of an RDoC motor domain to understand psychomotor symptoms in depression.RDoC 运动领域在理解抑郁症精神运动症状中的效用。
Psychol Med. 2019 Jan;49(2):212-216. doi: 10.1017/S0033291718003033. Epub 2018 Oct 16.
6
Prediction of response to drug therapy in psychiatric disorders.精神障碍药物治疗反应的预测。
Open Biol. 2018 May;8(5). doi: 10.1098/rsob.180031.
7
Access to the CNS: Biomarker Strategies for Dopaminergic Treatments.中枢神经系统的通路:多巴胺治疗的生物标志物策略。
Pharm Res. 2018 Feb 15;35(3):64. doi: 10.1007/s11095-017-2333-x.
8
What Can Different Motor Circuits Tell Us About Psychosis? An RDoC Perspective.不同的运动回路能告诉我们关于精神病的什么信息?从 RDoC 的角度来看。
Schizophr Bull. 2017 Sep 1;43(5):949-955. doi: 10.1093/schbul/sbx087.
9
Clinical predictors of therapeutic response to antipsychotics in schizophrenia.精神分裂症中抗精神病药物治疗反应的临床预测因素。
Dialogues Clin Neurosci. 2014 Dec;16(4):505-24. doi: 10.31887/DCNS.2014.16.4/mcarbon.
10
The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal.长效注射用抗精神病药在精神分裂症中的作用:批判性评价。
Ther Adv Psychopharmacol. 2014 Oct;4(5):198-219. doi: 10.1177/2045125314540297.